Andrew Franklin
Director of Finance/CFO at ALLIANCE PHARMA PLC
Net worth: 110 532 $ as of 30/12/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Peter Butterfield | M | 50 |
Maelor Laboratories Ltd.
![]() Maelor Laboratories Ltd. Medical DistributorsDistribution Services Part of Alliance Pharma Plc, Maelor Laboratories Ltd. is a British company that engages in selling and marketing pharmaceutical products and medical devices. The company is based in Chippenham, UK. Founded in 1997, Maelor Laboratories focuses on providing these products to the market.
Alliance Pharmaceuticals Ltd. (United Kingdom)
![]() Alliance Pharmaceuticals Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Part of Alliance Pharma Plc, Alliance Pharmaceuticals Ltd. is a British UK-based company founded in 1996 by John Dawson. The company is an international consumer healthcare business that offers trusted and proven brands to improve people's health and wellbeing. The company has a consistent track record of investing in both organic growth and acquisitions. The company works with a team of people, brands, and partners to achieve more for patients, healthcare providers, business partners, and investors. Peter Jonathan Butterfield has been the CEO of the company since 2010. | 15 years |
John Dawson | M | - |
Alliance Pharmaceuticals Ltd. (United Kingdom)
![]() Alliance Pharmaceuticals Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Part of Alliance Pharma Plc, Alliance Pharmaceuticals Ltd. is a British UK-based company founded in 1996 by John Dawson. The company is an international consumer healthcare business that offers trusted and proven brands to improve people's health and wellbeing. The company has a consistent track record of investing in both organic growth and acquisitions. The company works with a team of people, brands, and partners to achieve more for patients, healthcare providers, business partners, and investors. Peter Jonathan Butterfield has been the CEO of the company since 2010. | 29 years |
Joanna Le Couilliard | F | 61 |
Alliance Pharmaceuticals Ltd. (United Kingdom)
![]() Alliance Pharmaceuticals Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Part of Alliance Pharma Plc, Alliance Pharmaceuticals Ltd. is a British UK-based company founded in 1996 by John Dawson. The company is an international consumer healthcare business that offers trusted and proven brands to improve people's health and wellbeing. The company has a consistent track record of investing in both organic growth and acquisitions. The company works with a team of people, brands, and partners to achieve more for patients, healthcare providers, business partners, and investors. Peter Jonathan Butterfield has been the CEO of the company since 2010. | 6 years |
David John Cook | M | 58 |
Alliance Pharmaceuticals Ltd. (United Kingdom)
![]() Alliance Pharmaceuticals Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Part of Alliance Pharma Plc, Alliance Pharmaceuticals Ltd. is a British UK-based company founded in 1996 by John Dawson. The company is an international consumer healthcare business that offers trusted and proven brands to improve people's health and wellbeing. The company has a consistent track record of investing in both organic growth and acquisitions. The company works with a team of people, brands, and partners to achieve more for patients, healthcare providers, business partners, and investors. Peter Jonathan Butterfield has been the CEO of the company since 2010. | 11 years |
Richard Jones | M | 58 |
Alliance Pharmaceuticals Ltd. (United Kingdom)
![]() Alliance Pharmaceuticals Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Part of Alliance Pharma Plc, Alliance Pharmaceuticals Ltd. is a British UK-based company founded in 1996 by John Dawson. The company is an international consumer healthcare business that offers trusted and proven brands to improve people's health and wellbeing. The company has a consistent track record of investing in both organic growth and acquisitions. The company works with a team of people, brands, and partners to achieve more for patients, healthcare providers, business partners, and investors. Peter Jonathan Butterfield has been the CEO of the company since 2010. | 6 years |
Martin Sutherland | M | 56 | 2 years | |
Eva-Lotta Sjöstedt | F | 58 | 2 years | |
Camillo Pane | M | 54 | 1 years | |
Chris Chrysanthouc | M | - | 8 years | |
Kristof Leon Neirynck | M | 47 | 4 years | |
Richard McKenzie | M | 53 | 2 years | |
Stephen Martin Kidner | M | 57 |
Maelor Laboratories Ltd.
![]() Maelor Laboratories Ltd. Medical DistributorsDistribution Services Part of Alliance Pharma Plc, Maelor Laboratories Ltd. is a British company that engages in selling and marketing pharmaceutical products and medical devices. The company is based in Chippenham, UK. Founded in 1997, Maelor Laboratories focuses on providing these products to the market. | - |
Alexander James Hanbury Duggan | M | 55 |
Maelor Laboratories Ltd.
![]() Maelor Laboratories Ltd. Medical DistributorsDistribution Services Part of Alliance Pharma Plc, Maelor Laboratories Ltd. is a British company that engages in selling and marketing pharmaceutical products and medical devices. The company is based in Chippenham, UK. Founded in 1997, Maelor Laboratories focuses on providing these products to the market. | - |
Alex Duggan | M | - | 11 years | |
Julie Skinner | F | - | 2 years |
Connections Chart
Multi-company connection
Past Relations
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Anthony Richard Booley | M | - | 18 years | |
Andrew Leonard Smith | M | - | 12 years | |
Jeyan Heper | M | - | 1 years | |
Nigel Clifford | M | 66 | 6 years | |
Amir Rahim | M | - |
The University of Wales
| 7 years |
Janice Elizabeth Timberlake | F | - | 12 years | |
Ryan Lee | M | 56 |
The University of Wales
| 3 years |
David C. Salcfas | M | - |
The University of Wales
| 4 years |
Mohammad Zin bin Awang | M | 76 |
The University of Wales
| 1 years |
Hari Sugiharto | M | 79 |
The University of Wales
| 1 years |
Donald Bergstrom | M | 53 |
Genzyme Therapeutics Ltd.
![]() Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | 4 years |
Mark Everitt | M | - |
The University of Wales
| 3 years |
Simon Thomas | M | 61 |
The University of Wales
| 4 years |
Richard A. Moscicki | M | 73 |
Genzyme Therapeutics Ltd.
![]() Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | 2 years |
Dan Thomas | M | - | 15 years | |
Sze Yao Wang | M | 58 |
The University of Wales
| 4 years |
Harold Gittlemon | M | - |
The University of Wales
| 4 years |
Michael Francis | M | 59 |
The University of Wales
| 4 years |
Christina Rossi | F | 49 |
Genzyme Therapeutics Ltd.
![]() Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | 6 years |
Susan Moran | M | 55 |
Genzyme Therapeutics Ltd.
![]() Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | 4 years |
Demetra Kalogerou | M | 56 |
The University of Wales
| 4 years |
Khoon Lim | M | 60 |
The University of Wales
| 3 years |
Yau Chi Luk | M | 61 |
The University of Wales
| 4 years |
Mokgadi Khonziwe Nteta | F | 60 |
The University of Wales
| 4 years |
Arild Bjørn Hansen | M | 56 |
The University of Wales
| 3 years |
Henrik Lawaetz | M | 70 |
The University of Wales
| 3 years |
Warren Pratt | M | 71 |
The University of Wales
| 3 years |
Sandy Smith | M | 78 |
Genzyme Therapeutics Ltd.
![]() Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | 15 years |
Andrew J. Wilkinson | M | - |
The University of Wales
| 3 years |
Simon Biancardi | M | - |
The University of Wales
| 3 years |
Kam Yim Wong | M | 64 |
The University of Wales
| 1 years |
Roderick Kirkham | M | 64 |
The University of Wales
| 3 years |
Timothy J. Falla | M | 59 |
The University of Wales
| 4 years |
Robin Bellhouse | M | 61 | 1 years | |
Shiu Chung Mak | M | 63 |
The University of Wales
| 2 years |
Richard Asabia | M | 62 |
The University of Wales
| 2 years |
Wing Ho Ha | M | 62 |
The University of Wales
| 3 years |
Thomas Casdagli | M | 48 | 9 years | |
Mike Fischer | M | 67 |
The University of Wales
| 3 years |
Woon Jun Kong | M | 62 |
The University of Wales
| 4 years |
Mohamed Ibrahim bin A. Wahid | M | 63 |
The University of Wales
| 3 years |
Zulkifli bin Mohamad Razali | M | 65 |
The University of Wales
| 1 years |
Asmet bin Nasruddin | M | 58 |
The University of Wales
| 3 years |
Kesavan Nair | M | 61 |
The University of Wales
| 3 years |
Andrew Cunningham | M | - |
Genzyme Therapeutics Ltd.
![]() Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United Kingdom | 60 | 100% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Provenance des relations
- Stock Market
- Insiders
- Andrew Franklin
- Personal Network